Anika Therapeutics (ANIK) Assets Average (2011 - 2026)

Anika Therapeutics (ANIK) has reported Assets Average for 16 consecutive years, with $181.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 4.08% year-over-year to $181.4 million in Q2 2026; TTM through Jun 2026 was $181.4 million, a 4.08% decrease from a year earlier, with the FY2025 full-year figure at $196.5 million, down 16.98% from the prior year.
• Assets Average was $181.4 million for Q2 2026 at Anika Therapeutics, down from $184.8 million in the prior quarter.
• Over five years, Assets Average peaked at $350.9 million in Q3 2022 and troughed at $181.4 million in Q2 2026.
• A 5-year average of $268.0 million and a median of $265.2 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average retreated 0.23% in 2023 and fell 28.14% in 2025, its largest moves.
• Over 5 years, Assets Average stood at $348.4 million in 2022, then fell by 14.07% to $299.4 million in 2023, then decreased by 27.5% to $217.1 million in 2024, then decreased by 12.54% to $189.9 million in 2025, then decreased by 4.44% to $181.4 million in 2026.
• The last three Assets Average figures came in at $181.4 million (Q2 2026), $184.8 million (Q1 2026), and $189.9 million (Q4 2025), per Business Quant data.